Sagimet Biosciences (SGMT) Stock Price, Quote, News & History | Benzinga

SPY—QQQ707.87−0.27%BTC/USD—DIA—GLD—TLT80.06+0.01%

Sagimet Biosciences Inc (SGMT) Stock Price, Quote, News & History

SGMTNASDAQ

Trade with Public

Trade with Public

$8.02

-0.15-1.84%

Last update: Oct 16, 4:26 PM

$8.02

-0.15-1.84%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$8.15

Close

$8.02

Volume / Avg.

1.09M / 1.27M

Day Range

$7.94 - $8.25

52 Wk Range

4.50 - 11.45

Market Cap

$568.69M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

28

Short Interest

16.03%

Days to Cover

6.7

Recent Sagimet Biosciences Inc. News

Sagimet Biosciences Surges Forward With Successful Acne Clinical Data and Capital Raise

Sagimet reports positive 52-week Phase 3 trial data for denifanstat in acne patients and prices a $115 million stock offering.

Vandana Singh

This Illumina Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

Analysts upgraded Sagimet, Figure, Illumina, Martin Marietta and Waters, raising price targets and improving ratings.

Avi Kapoor

Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying

Biotechnology investing is a strange corner of the market. A company can own a drug that may eventually produce billions of dollars in sales and still find itself scrambling to raise enough cash to survive another

Tim Melvin

Legend Biotech, Sleep Number And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

US stock futures up, Nasdaq futures 1% higher. Legend Biotech (LEGN) priced 7.7 million ADSs at $29.35 each, shares down 9% in pre-market trading.

Avi Kapoor

Why Is Sagimet Biosciences Stock Trading Higher On Monday?

Sagimet shares surge as Phase 3 acne trial plans and $175M offering fund pipeline through 2028, with technicals showing strong momentum.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-41.72M

Investing Cash Flow (TTM)

629.00K

Financing Cash Flow (TTM)

164.66M

Free Cash Flow (TTM)

-41.72M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

123.57M

Analyst Trends and Forecast

1

Apr

1

May

2

Aug

2

1

Sep

3

Oct

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.1

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$330.50M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

2.26

Earnings Yield % (TTM)

-15.42%

Earnings Yield % (FWD)

-12.61%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$3.61

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$165.90M

Debt to Equity

0.01

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-